Table 2. Statistical association of cytoplasmic H score expression of ARHGAP18 and the clinicopathological parameters of the studied series.
ARHGAP18 cytoplasmic expression |
|
|
||
---|---|---|---|---|
Parameter | Low no. (%) | High no. (%) | χ2 | P-value |
Patients’ age | ||||
⩽50 yrs | 290 (79.0) | 77 (21.0) | 3.178 | 0.075 |
>50 yrs | 494 (83.6) | 97 (16.4) | ||
Menopausal status | ||||
Premenopausal | 303 (79.5) | 78 (20.5) | 2.270 | 0.132 |
Postmenopausal | 481 (83.4) | 96 (916.6) | ||
Grade | ||||
1 | 98 (76.0) | 31 (24.0) | 3.439 | 0.179 |
2 | 247 (82.3) | 53 (17.7) | ||
3 | 432 (82.9) | 89 (17.1) | ||
Mitotic figures | ||||
1 | 221 (82.5) | 47 (17.5) | ||
2 | 154 (78.6) | 42 (21.4) | 1.713 | 0.425 |
3 | 383 (82.7) | 80 (17.3) | ||
Pleomorphisms | ||||
1 | 8 (61.5) | 5 (38.5) | ||
2 | 249 (79.3) | 65 (20.7) | 6.015 | 0.049 |
3 | 500 (83.5) | 99 (16.5) | ||
Tubule formation | ||||
1 | 34 (75.6) | 11 (24.4) | ||
2 | 242 (78.6) | 66 (21.4) | 5.147 | 0.075 |
3 | 482 (84.0) | 92 (16.0) | ||
Axillary nodal stage | ||||
1 | 458 (80.2) | 113 (19.8) | ||
2 | 258 (84.9) | 46 (15.1) | 2.900 | 0.235 |
3 | 64 (82.1) | 14 (17.9) | ||
Tumour size | ||||
⩽2 cm | 437 (80.5) | 106 (19.5) | 1.581 | 0.209 |
>2 cm | 338 (83.7) | 66 (16.3) | ||
NPI | ||||
Good (<3.4) | 195 (78.9) | 52 (21.2) | ||
Moderate (3.41–5.4) | 431 (81.3) | 99 (18.7) | 17.898 | 0.010 |
Poor (⩾5.41) | 152 (87.4) | 22 (12.6) | ||
Vascular invasion | ||||
Negative | 485 (79.2) | 127 (20.8) | 7.617 | 0.006 |
Definite | 283 (86.5) | 44 (13.5) | ||
Tumour type | ||||
Ductal carcinoma No Special Type (NST) | 476 (82.4) | 102 (17.6) | ||
Tubular mixed | 125(79.1) | 33(20.9) | ||
Medullary-like | 21(91.3) | 2 (8.7) | 7.914 | 0.244 |
Invasive lobular | 63 (86.3) | 10 (13.7) | ||
Excellent Prognosis Special Type** | 26 (68.4) | 12 (31.6) | ||
Mixed NST and lobular | 32 (82.1) | 7 (17.9) | ||
Mixed NST and other special type | 16 (84.2) | 169 (18.2) |
Abbreviation: NPI=Nottingham Prognostic Index.
Excellent prognostic special types comprise: mucinous carcinoma, cribriform carcinoma, tubular carcinoma and invasive papillary carcinoma.